Skip to main content

Table 3 Patients with a PGA changea of 'good', 'excellent' or 'cleared', according to first treatment (assigned at baseline) and last treatment (the treatment that was being received at Week 12)*.

From: Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

 

Methotrexate

Cyclosporin

Corticosteroids

Combinedb

Retinoids

All patients

First treatment (n (%))

9/20 (45.0)

7/10 (70.0)

2/8 (25.0)

0/2 (0.0)

0/1 (0.0)

18/41 (43.9)

Last treatment (n (%))

9/18 (50.0)

9/12 (75.0)

4/8 (50.0)

1/2 (50.0)

0/1 (0.0)

23/41 (56.1)

  1. * At the investigators' discretion, six patients were switched between treatments during the study.
  2. aChange from baseline.
  3. bCombined systemic corticosteroids plus methotrexate.
  4. PGA, physician's global assessment.
Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us